{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T20:29:51Z","timestamp":1790886591683,"version":"4.1.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2016,1]]},"DOI":"10.1016\/j.clinthera.2015.11.008","type":"journal-article","created":{"date-parts":[[2015,12,16]],"date-time":"2015-12-16T16:10:23Z","timestamp":1450282223000},"page":"89-98.e1","source":"Crossref","is-referenced-by-count":14,"title":["Single-dose Pharmacokinetics and Pharmacodynamics of Canagliflozin, a Selective Inhibitor of Sodium Glucose Cotransporter 2, in Healthy Indian Participants"],"prefix":"10.1016","volume":"38","clinical-trial-number":[{"clinical-trial-number":"nct01748526","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Damayanthi","family":"Devineni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Polidori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Curtin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Stieltjes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewa","family":"Wajs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2015.11.008_bib1","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.diabres.2011.10.029","article-title":"IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030","volume":"94","author":"Whiting","year":"2011","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.clinthera.2015.11.008_bib2","unstructured":"World Health Organization: Diabetes Fact Sheet No. 312. Updated January 2015. http:\/\/www.who.int\/mediacentre\/factsheets\/fs312\/en\/. Accessed May 15, 2015."},{"key":"10.1016\/j.clinthera.2015.11.008_bib3","unstructured":"International Diabetes Federation IDF. Diabetes Atlas, 6th ed. 2013. http:\/\/www.idf.org\/diabetesatlas\/update-2014. Accessed May 20, 2015."},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2015.11.008_bib4","first-page":"S1","article-title":"Standards of medical care in diabetes","volume":"38","year":"2015","journal-title":"Diabetes Care"},{"issue":"Suppl 2","key":"10.1016\/j.clinthera.2015.11.008_bib5","doi-asserted-by":"crossref","first-page":"S264","DOI":"10.2337\/dc11-s223","article-title":"Therapy in the early stage: incretins","volume":"34","author":"Cernea","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2015.11.008_bib6","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1056\/NEJMoa066224","article-title":"Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy","volume":"355","author":"Kahn","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2015.11.008_bib7","doi-asserted-by":"crossref","first-page":"131","DOI":"10.2337\/diaclin.25.4.131","article-title":"Diabetes treatment, part 2: oral agents for glycemic management","volume":"25","author":"Fowler","year":"2007","journal-title":"Clin Diabetes"},{"key":"10.1016\/j.clinthera.2015.11.008_bib8","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1111\/dom.12054","article-title":"Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise","volume":"15","author":"Stenlof","year":"2013","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.clinthera.2015.11.008_bib9","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1210\/jc.2009-0473","article-title":"Sodium glucose cotransporter 2 inhibitors as a new treatment for diabetes mellitus","volume":"95","author":"Nair","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.clinthera.2015.11.008_bib10","doi-asserted-by":"crossref","first-page":"377","DOI":"10.2165\/11318680-000000000-00000","article-title":"Sodium-glucose co-transport inhibitors: progress and therapeutic potential in type 2 diabetes mellitus","volume":"70","author":"Neumiller","year":"2010","journal-title":"Drugs"},{"key":"10.1016\/j.clinthera.2015.11.008_bib11","doi-asserted-by":"crossref","first-page":"E867","DOI":"10.1210\/jc.2012-4205","article-title":"Validation of a novel method for determining the renal threshold for glucose excretion in untreated and canagliflozin-treated subjects with type 2 diabetes mellitus","volume":"98","author":"Polidori","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.clinthera.2015.11.008_bib12","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.2337\/dc12-2491","article-title":"Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial","volume":"36","author":"Schernthaner","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2015.11.008_bib13","unstructured":"Invokana (canagliflozin) [prescribing information]. India: Johnson & Johnson; 2015."},{"key":"10.1016\/j.clinthera.2015.11.008_bib14","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/cpdd.162","article-title":"Absolute oral bioavailability and pharmacokinetics of canagliflozin: A microdose study in healthy participants","volume":"4","author":"Devineni","year":"2015","journal-title":"Clinical Pharm Drug Dev"},{"key":"10.1016\/j.clinthera.2015.11.008_bib15","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.clinthera.2014.12.013","article-title":"Effect of hepatic or renal impairment on the pharmacokinetics of canagliflozin, a sodium glucose co-transporter 2 inhibitor","volume":"37","author":"Devineni","year":"2015","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2015.11.008_bib16","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1124\/dmd.113.056440","article-title":"Metabolism and excretion of canagliflozin in mice, rats, dogs, and humans","volume":"42","author":"Mamidi","year":"2014","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.clinthera.2015.11.008_bib17","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1002\/cpdd.151","article-title":"Effect of food on the pharmacokinetics of canagliflozin, a sodium glucose co-transporter 2 inhibitor, and assessment of dose proportionality in healthy participants","volume":"4","author":"Devineni","year":"2015","journal-title":"Clinical Pharm in Drug Dev"},{"key":"10.1016\/j.clinthera.2015.11.008_bib18","doi-asserted-by":"crossref","first-page":"129","DOI":"10.5414\/CP202218","article-title":"Single- and multiple-dose pharmacokinetics and pharmacodynamics of canagliflozin, a selective inhibitor of sodium glucose co-transporter 2, in healthy participants","volume":"53","author":"Devineni","year":"2015","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2015.11.008_bib19","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1002\/jcph.88","article-title":"Pharmacokinetics and pharmacodynamics of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in subjects with type 2 diabetes mellitus","volume":"53","author":"Devineni","year":"2013","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2015.11.008_bib20","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1111\/j.1463-1326.2011.01406.x","article-title":"Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects","volume":"13","author":"Sha","year":"2011","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.clinthera.2015.11.008_bib21","doi-asserted-by":"crossref","first-page":"e105638","DOI":"10.1371\/journal.pone.0105638","article-title":"Pharmacodynamic effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, from a randomized study in patients with type 2 diabetes","volume":"9","author":"Sha","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.clinthera.2015.11.008_bib22","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.2337\/dc12-2391","article-title":"Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion: results of a randomized, placebo-controlled study","volume":"36","author":"Polidori","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2015.11.008_bib23","doi-asserted-by":"crossref","first-page":"53","DOI":"10.5414\/CPP38053","article-title":"Predictability of the effects of race or ethnicity on pharmacokinetics of drugs","volume":"38","author":"Johnson","year":"2000","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2015.11.008_bib24","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/clpt.2008.141","article-title":"The role of ethnicity in variability in response to drugs: focus on clinical pharmacology studies","volume":"84","author":"Yasuda","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2015.11.008_bib25","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1016\/j.clinthera.2015.04.015","article-title":"Pharmacokinetics, pharmacodynamics, and safety of single-dose canagliflozin in healthy Chinese subjects","volume":"37","author":"Chen","year":"2015","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2015.11.008_bib26","unstructured":"Sakai M, Matsukawa M, Azuma J, et al. A study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of a new SGLT2 inhibitor TA-7284\/canagliflozin in healthy Japanese subjects. Presented at: 53rd Annual meeting of the Japan Diabetes Society, Okayama, Japan, May 27\u201329, 2010."},{"key":"10.1016\/j.clinthera.2015.11.008_bib27","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1111\/dom.12149","article-title":"Efficacy and safety of canagliflozin in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, 12-week study","volume":"15","author":"Inagaki","year":"2013","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.clinthera.2015.11.008_bib28","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.2337\/dc11-1926","article-title":"Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes","volume":"35","author":"Rosenstock","year":"2012","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2015.11.008_bib29","unstructured":"U.S. Food and Drug Administration. Guidance for Industry: Bioanalytical Method Validation. 2001. http:\/\/wwwfdagov\/downloads\/Drugs\/Guidances\/ucm070107pdf. Accessed July 2, 2015."},{"key":"10.1016\/j.clinthera.2015.11.008_bib30","doi-asserted-by":"crossref","first-page":"461","DOI":"10.7326\/0003-4819-130-6-199903160-00002","article-title":"A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation","volume":"130","author":"Levey","year":"1999","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clinthera.2015.11.008_bib31","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1007\/s00125-013-3039-1","article-title":"Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial","volume":"56","author":"Lavalle-Gonz\u00e1lez","year":"2013","journal-title":"Diabetologia"},{"key":"10.1016\/j.clinthera.2015.11.008_bib32","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1111\/j.1463-1326.2012.01558.x","article-title":"Canagliflozin improves glycaemic control over 8 days in subjects with type 2 diabetes not optimally controlled on insulin","volume":"14","author":"Devineni","year":"2012","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.clinthera.2015.11.008_bib33","article-title":"Population pharmacokinetic modeling of canagliflozin in healthy volunteers and patients with type 2 diabetes mellitus","author":"Hoeben","year":"2015","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.clinthera.2015.11.008_bib34","doi-asserted-by":"crossref","unstructured":"Prasanna Kumar KM, Mohan V, Sethi B, et al. Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus from India. Presented at: 10th Biennial International Diabetes Federation Western Pacific Region Congress, Suntec City, Singapore, November 21\u201324, 2014.","DOI":"10.4103\/2230-8210.179996"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291815012370?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291815012370?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,16]],"date-time":"2018-09-16T19:51:34Z","timestamp":1537127494000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291815012370"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,1]]}},"alternative-id":["S0149291815012370"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2015.11.008","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2016,1]]}}}